PRF Technologies Ltd. PRFX 深 滬
已收盤 02-06 16:00:00 美东时间
2.96
-0.062
-2.05%
華盛通- 最 高3.60
- 今 開3.40
- 成交量 25.88万股
- 最 低 2.76
- 昨 收 3.022
- 總市值 1158.94万
- 52周最高 5.4699
- 市盈率 靜 --
- 換手率 6.61%
- 52周最低 0.5821
- 委 比 94.17%
- 總股本 391.53万
- 歷史最高 1884.00
- 量 比 1.14
- 振 幅 27.80%
- 歷史最低 0.5821
- 每 手 1
- 風險率 3.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why PainReform Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Shares of PainReform Ltd. (NASDAQ:PRFX) rose sharply in pre-market trading. The...
01-16 17:38
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
PainReform Ltd. and LayerBio, Inc. announced safety data supporting the continued development of OcuRing™-K, a drop-less, sustained-release ocular drug delivery platform for use in cataract surgery. Preclinical rabbit studies and a Phase I clinical study demonstrated a favorable safety profile, with no treatment-related safety concerns observed. The platform's sustained-release mechanism aims to minimize local irritation and systemic exposure. Pa...
01-12 14:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
PainReform Commences Development Plan For OcuRing-K, LayerBio's Patented, Drop-Less, Intraoperatively Administered Sustained-Release Ocular Therapy
PainReform Ltd. (NASDAQ:PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio's patented, drop-less, intraoperatively administered
2025-12-02 22:20
PainReform shares are trading higher after the company announced its solar energy business unit was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program.
PainReform shares are trading higher after the company announced its solar ener...
2025-11-06 01:26
PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform Ltd. reported progress in its dual strategy to reformulate therapeutics and develop AI-driven solar technologies. The company completed a majority investment in LayerBio, acquiring its OcuRing™-K, a dropless cataract therapy targeting a $9B market. PainReform advanced PRF-110, showing early efficacy in postoperative pain, while spending on R&D fell to $0.3M. DeepSolar expanded with a Smart Energy Management app, joined NVIDIA's Connect...
2025-10-01 13:27
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose sharply in pre-market...
2025-08-20 19:24
PainReform/DeepSolar Accepted into NVIDIA Connect Program
DeepSolar, a business unit of PainReform, has been accepted into NVIDIA's Connect Program to enhance its AI-driven solar forecasting platform, DeepSolar Predict, improving weather forecast accuracy by up to 50% and optimizing energy asset performance. This collaboration aims to address critical industry needs, including reducing imbalance penalties, maximizing revenue through better energy timing, and strengthening grid stability. The program pro...
2025-08-19 12:30
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. has acquired a majority stake in LayerBio Inc., a biotech company developing "dropless" solutions for ophthalmic surgery. The investment focuses on advancing LayerBio’s OcuRing™-K, a sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic medication during cataract surgery, addressing patient compliance issues and reducing reliance on multiple medications. This transaction positions PainReform to add...
2025-08-13 12:30
PainReform Signs Strategic Investment Agreement With LayerBio To Expand Non-Opiate Pain Management Pipeline Into Opthamology
PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing
2025-07-10 20:38
